Followers | 4054 |
Posts | 151764 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Monday, May 04, 2020 8:08:42 AM
Recent OGEN News
- Oragenics Develops Automated Intranasal Device for Treating Concussed Patients • GlobeNewswire Inc. • 06/27/2024 12:30:40 PM
- Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 06/26/2024 08:47:15 PM
- Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Oragenics, Inc. Announces Proposed Public Offering • GlobeNewswire Inc. • 06/24/2024 10:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:24 PM
- Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 01:27:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:17 PM
- Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:00:41 PM
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:00:22 PM
- Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 05:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:14:33 PM
- Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
- Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM